ATE359065T1 - Verwendung von einem insulin-sensibilisator in der behandlung von alopecia - Google Patents

Verwendung von einem insulin-sensibilisator in der behandlung von alopecia

Info

Publication number
ATE359065T1
ATE359065T1 AT01914437T AT01914437T ATE359065T1 AT E359065 T1 ATE359065 T1 AT E359065T1 AT 01914437 T AT01914437 T AT 01914437T AT 01914437 T AT01914437 T AT 01914437T AT E359065 T1 ATE359065 T1 AT E359065T1
Authority
AT
Austria
Prior art keywords
treatment
insulin
isis
alopecia
insulin sensitizer
Prior art date
Application number
AT01914437T
Other languages
English (en)
Inventor
Rozlyn A Krajcik
Norman Orentreich
Original Assignee
Orentreich Foundation For The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orentreich Foundation For The filed Critical Orentreich Foundation For The
Application granted granted Critical
Publication of ATE359065T1 publication Critical patent/ATE359065T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01914437T 2000-02-23 2001-02-23 Verwendung von einem insulin-sensibilisator in der behandlung von alopecia ATE359065T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18439800P 2000-02-23 2000-02-23

Publications (1)

Publication Number Publication Date
ATE359065T1 true ATE359065T1 (de) 2007-05-15

Family

ID=22676712

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01914437T ATE359065T1 (de) 2000-02-23 2001-02-23 Verwendung von einem insulin-sensibilisator in der behandlung von alopecia

Country Status (7)

Country Link
US (2) US7105573B2 (de)
EP (1) EP1267850B1 (de)
AT (1) ATE359065T1 (de)
AU (2) AU3982601A (de)
CA (1) CA2406871A1 (de)
DE (1) DE60127827T2 (de)
WO (1) WO2001062237A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809310B1 (fr) * 2000-05-26 2004-02-13 Centre Nat Rech Scient Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US20030220300A1 (en) * 2002-05-14 2003-11-27 Hwang Cheng Shine Reduction of hair growth
FR2845000B1 (fr) * 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
US6787163B2 (en) * 2003-01-21 2004-09-07 Dennis H. Harris Therapeutic treatment for blood sugar regulation
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200
US20080125403A1 (en) * 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7618956B2 (en) 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
FR2887442A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzyl-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
FR2887444A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
FR2901135B1 (fr) * 2006-05-22 2017-12-08 Oreal Utilisation de modulateurs de la glycolyse comme agents diminuant la proliferation des keratinocytes
FR2901133B1 (fr) * 2006-05-22 2013-04-26 Oreal Utilisation de modulateurs de la glycolyse comme agents anti-age
US20080103116A1 (en) * 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
US8796282B2 (en) * 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
DE102008012988A1 (de) * 2008-03-07 2009-09-10 S.W. Patentverwertungs Ltd. Zusammensetzung und Verwendungen zur Beeinflussung des Haarwachstums
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
BR112016029338A2 (pt) 2014-07-29 2017-08-22 Therapeuticsmd Inc creme transdérmico
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
GB201518979D0 (en) * 2015-10-27 2015-12-09 Univ Leuven Kath Treatment of hepatic steatosis related oligo-ovulation
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3449897B1 (de) * 2016-04-27 2024-07-17 Kobayashi Pharmaceutical Co., Ltd. Haarwuchsmittel
IL268345B (en) 2017-02-24 2022-08-01 Univ California Preparations and methods for promoting hair growth with mpc1 inhibitors
EP3644989A4 (de) 2017-06-30 2021-07-14 The Regents of the University of California Zusammensetzungen und verfahren zur modulation des haarwachstums
AU2018339064A1 (en) * 2017-09-29 2020-02-27 The Regents Of The University Of California Compositions and methods for modulating hair growth
JP7450324B2 (ja) * 2017-11-01 2024-03-15 小林製薬株式会社 Ｄ－ｃｈｉｒｏ－イノシトールを含む組成物
JP7127978B2 (ja) * 2017-11-01 2022-08-30 小林製薬株式会社 Ｄ－ｃｈｉｒｏ－イノシトールを含む組成物
JP7127979B2 (ja) * 2017-11-01 2022-08-30 小林製薬株式会社 Ｄ－ｃｈｉｒｏ－イノシトールを含む組成物
CN108131126A (zh) * 2018-02-09 2018-06-08 徐工集团工程机械有限公司 凿岩机的控制系统、凿岩台车以及控制方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3203M (fr) 1964-01-30 1965-03-22 Carl Joachim Kleinwichs Teinture capillaire antiseptique, notamment pour le traitement des affections du cuir chevelu.
BE793229A (fr) * 1971-12-23 1973-06-22 Merck & Co Inc Derives de guanidines a action anti-acneique
FR2320735A1 (fr) * 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
US4684635A (en) 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
JPH04504847A (ja) 1989-03-08 1992-08-27 ザ　ユニバーシティ　オヴ　バージニア　パテント　ファウンデーション インスリン抵抗性糖尿病のための食事用補添物
US5292747A (en) 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
US5043162A (en) 1990-09-05 1991-08-27 Trager Seymour F Hair growth promoter
US5091596A (en) 1990-12-20 1992-02-25 Univ. Of Va. Alumni Patents Foundation Method for producing chiro-inositol
US5407944A (en) 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
FR2708854B1 (fr) 1993-08-13 1995-10-13 Oury Jean Pierre Maurice Composition contre la chute des cheveux et la fragilité des ongles.
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
IL107167A (en) * 1993-10-03 2000-01-31 Raziel Lurie Compositions containing relaxin for treatment of alopecia and related conditions
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5550166A (en) 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
GB9512290D0 (en) * 1995-06-16 1995-08-16 Moorfields Eye Hospital Uses of polyhexanide

Also Published As

Publication number Publication date
US20020143039A1 (en) 2002-10-03
US20070066661A1 (en) 2007-03-22
EP1267850A2 (de) 2003-01-02
AU2001239826B2 (en) 2006-06-15
AU3982601A (en) 2001-09-03
EP1267850B1 (de) 2007-04-11
CA2406871A1 (en) 2001-08-30
DE60127827T2 (de) 2007-12-27
WO2001062237A3 (en) 2002-06-13
US7105573B2 (en) 2006-09-12
WO2001062237A2 (en) 2001-08-30
DE60127827D1 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
ATE359065T1 (de) Verwendung von einem insulin-sensibilisator in der behandlung von alopecia
Price Treatment of hair loss
Manabe et al. Guidelines for the diagnosis and treatment of male‐pattern and female‐pattern hair loss, 2017 version
Jung et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride
Yemisci et al. Effects and side‐effects of spironolactone therapy in women with acne
NO20072599L (no) Inhibitorer av 11-beta-hydroksyl steroid dehydrogenase Type 1 og fremgangsmater for anvendelse derav
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
Kim et al. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata
TW200626156A (en) Amido compounds and their use as pharmaceuticals
NO20065442L (no) Amidoforbindelser og deres anvendelse som legemidler
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
ATE103813T1 (de) Topische metronidazol-formulationen und deren verwendung als arzneimittel.
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
Dluzen et al. Estrogen, anti‐estrogen, and gender: differences in methamphetamine neurotoxicity
Deshpande et al. Extensive alopecia areata: not necessarily recalcitrant to therapy!
Alomar et al. Topical tacrolimus 0.1% ointment (Protopic®) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema
Brenner et al. Improvement in androgenetic alopecia in 53–76‐year‐old men using oral finasteride
Ranjan et al. A comparative study of two modalities, 4% hydroquinone versus 30% salicylic acid in periorbital hyperpigmentation and assessment of quality of life before and after treatment
TW200511996A (en) The use of steroids to treat persons suffering from ocular disorders
Unal Use of adapalene in alopecia areata: Efficacy and safety of mometasone furoate 0.1% cream versus combination of mometasone furoate 0.1% cream and adapalene 0.1% gel in alopecia areata
Anitha et al. Finasteride-its impact on sexual function and prostate cancer
DE69722809D1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)-antagonisten und inhibitoren der hautmastzell-degranulation
Pascual et al. Tacrolimus ointment (Protopic) for atopic dermatitis.
Canavan et al. Lichen planopilaris in the setting of hair sunscreen spray
ATE420631T1 (de) Kosmetische und/oder pharmazeutische zubereitung enthaltend dimthylsulphone und einen sonnenfilter für die behandlung und die prävention von reizungen, entzündungen und hauterythema

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties